{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:52Z","timestamp":1794048832117,"version":"4.8.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijantimicag.2023.106905","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T02:27:42Z","timestamp":1687919262000},"page":"106905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Respiratory fluoroquinolone monotherapy vs. \u03b2-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-4531","authenticated-orcid":false,"given":"Sang-Ho","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Cesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Arthur Chandos","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishkantha","family":"Arulkumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1042-6350","authenticated-orcid":false,"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106905_bib0001","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0002","first-page":"139","article-title":"Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study","volume":"12","author":"Marrie","year":"2005","journal-title":"Can Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0003","unstructured":"National Institute for Health and Care Excellence [NICE]. Pneumonia in adults. https:\/\/www.nice.org.uk\/guidance\/qs110. 2016."},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0004","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/13696998.2022.2090734","article-title":"Hospitalization costs of adult community-acquired pneumonia in England","volume":"25","author":"Campling","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0005","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.rmed.2013.04.003","article-title":"Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study","volume":"107","author":"Arnold","year":"2013","journal-title":"Respir Medicine"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253118","article-title":"Population-based incidence and mortality of community-acquired pneumonia in Germany","volume":"16","author":"Theilacker","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0007","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/S1473-3099(22)00510-2","article-title":"Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the Global Burden of Disease Study 2019","volume":"22","year":"2022","journal-title":"Lancet Infect Diseases"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0008","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1183\/09031936.00092507","article-title":"Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment","volume":"32","author":"Kothe","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1183\/09031936.00128107","article-title":"Early mortality in patients with community-acquired pneumonia: causes and risk factors","volume":"32","author":"Garcia-Vidal","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0011","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/thx.2003.017756","article-title":"Risk factors of treatment failure in community-acquired pneumonia: implications for disease outcome","volume":"59","author":"Menendez","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0012","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0013","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/cix549","article-title":"Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus","volume":"65","author":"Musher","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.106905_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community-acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0015","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.idc.2012.11.004","article-title":"Does empirical therapy with a fluoroquinolone or the combination of a beta-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?","volume":"27","author":"Ruhe","year":"2013","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0017","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2015.04.010","article-title":"Fluoroquinolones or macrolides alone versus combined with beta-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis","volume":"46","author":"Raz-Pasteur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0018","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ajem.2018.01.079","article-title":"Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis","volume":"36","author":"Zhang","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0019","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11596-006-0411-0","article-title":"Efficacy and safety of intravenous moxifloxacin verus cefoperazone with azithromycin in the treatment of community-acuquired pneumonia","volume":"26","author":"Xu","year":"2006","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10096-003-1060-x","article-title":"Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia","volume":"23","author":"Erard","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0021","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1086\/498149","article-title":"Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalzed patients with community-acquired pneumonia who received initial parenteral therapy","volume":"41","author":"Welte","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0022","series-title":"Proceedings of the European Respiratory Society 13th Annual Congress","article-title":"No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo","author":"Ramirez","year":"2003"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0023","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00151829-200403050-00006","article-title":"Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia","volume":"3","author":"Zervos","year":"2004","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0025","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0026","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0027","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0028","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0149-2918(02)80034-0","article-title":"A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0029","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/378406","volume":"38","author":"Fogarty","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10096-005-1347-1","article-title":"Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for non-severe community-acquired pneumonia in adults with risk factors","volume":"24","author":"Portier","year":"2005","journal-title":"Eur Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0031","first-page":"245","article-title":"Multicentre clinical study on levofloxacin intravenous injection for treatment of community-acquired pneumonia","volume":"26","author":"Zhang","year":"2006","journal-title":"Int J Respir"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0032","first-page":"321","article-title":"An open-label, randomized comparison of levofloxacin and amoxicillin\/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia","volume":"30","author":"Lin","year":"2007","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0033","first-page":"594","article-title":"A comparison of levofloxacin alone and cefuroxime combined with azithromycin for patients with community-acquired pneumonia","volume":"17","author":"Zhao","year":"2007","journal-title":"Chin J Nosocomiol"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0034","first-page":"1457","article-title":"Sequential moxifloxacin therapy in the treatment of elderly patients with community-acquired pneumonia: clinical evaluation","volume":"28","author":"Huang","year":"2008","journal-title":"Acta Univ Med Nanjing"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0035","first-page":"102","article-title":"A randomized controlled multicentre clinical trial of levofloxacin sequential therapy compared with combination therapy with cefuroxime and azithromycin in patients with community-acquired pneumonia","volume":"8","author":"Shao","year":"2008","journal-title":"Chin J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0036","first-page":"3105","article-title":"Comparison of moxifloxacin and cefuroxime combined with azithromycin for patients with community-acquired pneumonia","volume":"19","author":"Gao","year":"2009","journal-title":"Chin J Nosocomiol"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0037","first-page":"1532","article-title":"A comparison between levofloxacin and cefuroxime with azithromycin in community-acquired pneumonia","volume":"12","author":"Li","year":"2009","journal-title":"Chin Gen Pract"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0038","first-page":"962","article-title":"Efficacy and cost-effectiveness analysis of moxifloxacin hydrochloride and combination of ceftriaxone sodium with azithromycin in the treatment of moderate to severe community acquired pneumonia in elderly patients","volume":"18","author":"Yang","year":"2009","journal-title":"Chin J New Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0039","first-page":"349","article-title":"Clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia","volume":"10","author":"Liu","year":"2010","journal-title":"Chin J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0040","first-page":"3400","article-title":"Clinical observation of moxifloxacin versus ceftriaxone combined with azithromycin in the treatment of community acquired pneumonia","volume":"21","author":"Han","year":"2010","journal-title":"Chin Pharm"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0041","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF03261911","article-title":"High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study","volume":"32","author":"Lee","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0042","first-page":"587","article-title":"Efficacy of levofloxacin in the treatment of community-acquired pneumonia","volume":"29","author":"L\u00f3pez-V\u00e9jar","year":"2013","journal-title":"Med Intern Mex"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0043","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0044","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1574891X13666181024154526","article-title":"Levofloxacin versus ceftriaxone and azithromycin combination in the treatment of community-acquired pneumonia in hospitalized patients","volume":"13","author":"Izadi","year":"2018","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20949","article-title":"Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0046","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00968-19","article-title":"Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program","volume":"57","author":"Waites","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0047","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3390\/idr13030073","article-title":"Update on the epidemiology of macrolide-resistant Mycoplasma pneumoniae in Europe: a systematic review","volume":"13","author":"Loconsole","year":"2021","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0048","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1128\/AAC.01421-12","article-title":"Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance","volume":"56","author":"Yoo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0049","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/antibiotics10101216","article-title":"Integrating the human and animal sides of mycoplasmas resistance to antimicrobials","volume":"10","author":"Pereyre","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0050","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14740338.2019.1665022","article-title":"An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms\/dissections disseminated by the Food and Drug Administration and the European Medicines Agency","volume":"18","author":"Bennett","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0051","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13054-022-04055-4","article-title":"Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial","volume":"26","author":"Karakike","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106905_bib0052","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/thoraxjnl-2019-214054","article-title":"Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis","volume":"76","author":"Montes-Andujar","year":"2021","journal-title":"Thorax"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300184X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300184X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:47:42Z","timestamp":1760377662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792300184X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S092485792300184X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106905","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Respiratory fluoroquinolone monotherapy vs. \u03b2-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106905"}}